The European Union has reached a deal with Pfizer and BioNTech for 300 million additional doses of their COVID-19 vaccine, the head of the European Commission says, in a move that would give the EU nearly half of the firms' global output for 2021.
Subscribe now for unlimited access.
$0/
(min cost $0)
or signup to continue reading
Pfizer has said it can produce globally up to 1.3 billion doses this year.
The new agreement with the EU comes on top of another order for 300 million doses that the bloc agreed in November with Pfizer and its German partner BioNTech.
"We now have agreed with BioNTech and Pfizer to extend this contract," European Commission President Ursula von der Leyen said.
"With the new agreement we could purchase a total of up to an additional 300 million doses of the BioNTech vaccine."
The move allows EU governments to order new doses from April, von der Leyen said, as the 27-nation bloc races to ramp up the vaccination of its 450 million people.
Each recipient of the Pfizer vaccine needs two doses to develop maximum protection.
Von der Leyen said 75 million of the additional doses would be delivered in the second quarter of this year, and the rest by the end of 2021.
The agreement includes a potential immediate order for 200 million doses and an additional option to buy another 100 million, the Commission said.
Doses are usually shared among EU states in proportion to their population.
Australian Associated Press
